Why FDA’s reduced exposure marketing order for IQOS is not a reliable global model

3/25/21–Lauren Lempert, Stella Bialous, and Stanton Glantz recently published “FDA’s reduced exposure marketing order for IQOS: why it is not a reliable global model” in Tobacco Control to explain what happened in the US and why the FDA process — which followed US law — is not a good model for the rest of the world. They argue that FDA should not have even authorized reduced exposure claims. Read